NCT06059547 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06059547
Title	Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer
Recruitment	Active, not recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	CatalYm GmbH
Indications	bladder urothelial carcinoma
Therapies	Nivolumab CTL-002 + Nivolumab
Age Groups:	adult \| senior
Covered Countries	ITA

Filter rows:

Showing 1 to 8 of 8 entries

Facility	City	Zip	Country	Details
A.O.U. Città della Salute e della Scienza di Torino	Torino	10126	Italy	Details
ASL Salerno, Ospedale Andrea Tortora	Pagani	84016	Italy	Details
Azienda Ospedaliera Ordine Mauriziano di Torino Ospedale Umberto I , SCDU Oncologia	Torino	10128	Italy	Details
Fondazione IRCCS Istituto Nazionale dei Tumori	Milano	20133	Italy	Details
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC Oncologia Medica	Roma	00168	Italy	Details
IRCCS Ospedale San Raffaele Hospital Vita-Salute San Raffaele University	Milano	20132	Italy	Details
Istituto Nazionale Tumori IRCCS - Fondazione Pascale	Napoli	80131	Italy	Details
Istituto Oncologico Veneto, IOV - IRCCS	Padova	35128	Italy	Details

Showing 1 to 8 of 8 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT06059547Clinical Trial Detail